Safety Information

We encourage our patients to report negative side effects of prescription drugs to the FDA. Visit fda.gov/medwatch or call 1-800-FDA-1088. If you have a medical emergency, call 911 immediately.

All Healsend advertisements are paid for by Healsend. Advertisements may include paid actors. Results may vary and outcomes are not guaranteed.

Healsend offers and/or facilitates access to licensed medical professional consultations. Healsend is NOT a medical provider or pharmacy. Healsend provides software and technology services only.

Special advertising offers may be available for up to 24 hours after removal of the original advertisement. Healsend reserves the right to adjust pricing. "Same price per dose" offers are subject to additional terms.

All prescription medications require a consultation and a prescription. Prescriptions are solely determined by a licensed medical professional. Access to prescription medications is not guaranteed.

Compounded medications are prepared by licensed USA-based 503A or 503B pharmacies. Compounded medications are NOT FDA-approved. They may be prescribed during periods of drug shortage or for individual patient needs.

Healsend does not claim ownership over brand-name FDA-approved medications. All trademarks belong to their respective owners.

For questions or concerns, visit Healsend.com.

*This medication is not FDA-regulated as a compounded formulation.

WARNING

Seek emergency help if you have symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; very rapid heartbeat.

Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.

Women of childbearing age should use adequate contraception during treatment. Stop taking semaglutide at least 2 months before a planned pregnancy due to the long half-life of the drug.

Drug Interactions

Semaglutide slows gastric emptying, which may impact the absorption of concomitantly administered oral medications. Use with insulin or insulin secretagogues may increase the risk of hypoglycemia; dose reduction may be required.

BLACK BOX WARNING — Thyroid C-Cell Tumors

Semaglutide causes thyroid C-cell tumors in rodents at clinically relevant exposures. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.

Semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and the symptoms of thyroid tumors.

*This medication is not FDA-regulated as a compounded formulation.

WARNING

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether tirzepatide causes thyroid tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients to report symptoms such as a mass in the neck, dysphagia, dysphonia, or dyspnea.

Serious Side Effects

• Pancreatitis: discontinue if suspected
• Hypoglycemia, especially when used with insulin or sulfonylureas
• Acute kidney injury
• Serious hypersensitivity reactions (angioedema, anaphylaxis)
• Acute gallbladder disease
• Diabetic retinopathy complications

Common Side Effects

• Nausea, diarrhea, vomiting, constipation
• Abdominal pain, dyspepsia
• Decreased appetite
• Fatigue, dizziness
• Injection site reactions

Drug Interactions

Oral contraceptives: administer oral contraceptives at least 4 weeks before initiating tirzepatide and for 4 weeks after each dose increase, as tirzepatide may lower the effect of oral contraceptives. Consider switching to a non-oral contraceptive or adding a barrier method during dose escalation.

Common Side Effects

Injection: Flushing, warmth, tingling, nausea, fatigue, headache, injection-site reactions.

Nasal Spray: Nasal irritation, headache, mild flushing.

More Serious Side Effects

Allergic reactions (rash, difficulty breathing); contact your provider immediately if these occur.

Warnings

• Limited long-term human safety data
• Not FDA-approved for any specific indication
• Discuss duration of therapy and monitoring with your provider

Contraindications

• Known allergy to NAD+ or formulation components
• Active cancer (discuss with oncologist)

Drug Interactions

May theoretically interact with PARP inhibitors. Inform your provider of all medications and supplements.

Pregnancy & Breastfeeding

Insufficient data; avoid unless directed by your provider.

Storage

Refrigerate at 2–8°C; protect from light. Do not use if discolored or if particulate matter is visible.

Have Questions?

Contact your Healsend provider through the platform messaging system.

Safety Information

Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release growth hormone.

Common Side Effects

• Injection site reactions (redness, pain, swelling)
• Flushing, headache, dizziness, nausea

Less Common / Rare Side Effects

• Changes in taste, hyperactivity, somnolence
• Difficulty swallowing (rare)

Warnings

• May increase IGF-1 levels; routine monitoring recommended
• Hypothyroidism may reduce response; treat underlying thyroid conditions before or during therapy

Contraindications

• Known hypersensitivity to sermorelin or formulation components
• Active malignancy

Drug Interactions

• Glucocorticoids may blunt the effect on growth hormone release
• Insulin and anti-diabetic agents: monitor glucose closely

Pregnancy & Breastfeeding

Category C; insufficient human data. Avoid unless benefits outweigh risks as determined by your provider.

Storage

Refrigerate at 2–8°C. Reconstituted solutions should be used within the timeframe specified by the pharmacy, typically within 30 days.

Have Questions?

Contact your Healsend provider through the platform messaging system.

*This medication is not FDA-regulated as a compounded nasal spray formulation.

WARNING

PT-141 can cause transient increases in blood pressure. Do not use if you have cardiovascular disease or uncontrolled hypertension. Blood pressure typically returns to baseline within 12 hours.

Drug Interactions

• Naltrexone: Reduces effectiveness; avoid co-administration
• Antihypertensives: Monitor blood pressure; effects may interact
• Do not use with other melanocortin agonists

Contraindications

• Cardiovascular disease or uncontrolled hypertension
• Pregnancy or breastfeeding
• Hypersensitivity to bremelanotide or formulation components

Common Side Effects

• Flushing (most common)
• Nausea, headache
• Nasal congestion or irritation
• Transient blood pressure increase
• Hyperpigmentation with frequent use (typically fades after discontinuation)

Storage

Store at room temperature (15–30°C), away from heat and light. Do not freeze. Discard per compounding pharmacy guidelines.